Short interest in the company has seen 16.69 Million shares shorted with days to cover at 8.88.Wall Street analysts have a consensus price target for the stock at $33, which means that the shares’ value could jump 88.46% from current levels. Year-ago sales stood $90Million and $13.15 Million respectively for this quarter and the next, and analysts expect sales will grow by 30366.7% for the current quarter and 77.2% for the next.If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -5.8% over the past 5 years.
None have rated the stock as Underweight.
Food and Drug Administration Accepts Karyopharm's Supplemental New Drug Application for XPOVIO(R) (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of TherapyHematological Cancers Market 2020 Research Report With COVID-19 Update, Growth Strategy and Industry Development to 2026Karyopharm Establishes Partnership with National Cancer Institute to Advance XPOVIO(R) (selinexor) ResearchKaryopharm Establishes Partnership with National Cancer Institute to Advance XPOVIO(R) (selinexor) ResearchGlobal Diffuse Large B Cell Lymphoma Drug Market 2020 Industry Emerging Trend, Market Players, Revenue Insights to 2026Nicotinamide Phosphoribosyltransferase Market 2020 Research Report With COVID-19 Update, Growth Strategy and Industry Development to 2026Synovial Sarcoma Treatment Market 2020 Research Report With COVID-19 Update, Growth Strategy and Industry Development to 2026Global Neuroendocrine Tumor Drug Market 2020 Current and Future Market Landscape Analysis 2026Global Nicotinamide Phosphoribosyl Transferase Market 2020 Industry Segmentation, CAGR Status, Leading Trends, and Forecast To 2026Leiomyosarcoma Drug Market 2020 Research Report With COVID-19 Update, Growth Strategy and Industry Development to 2026Global Nicotinamide Phosphoribosyltransferase Market 2020 Segmentation Analysis, Key Players, Industry Share and Forecast by 2025Global Synovial Sarcoma Treatment Market 2020 Industry Scenario, Strategies, Growth Factors and Forecast to 2025Karyopharm Announces Preliminary Unaudited Second Quarter Product Sales for XPOVIO(R) (selinexor)Karyopharm Announces Preliminary Unaudited Second Quarter Product Sales for XPOVIO(R) (selinexor)Global Neuroendocrine Tumor Drug Market 2020 Industry Analysis, Key Players Data, Growth Factors, Share, Opportunities and Forecast to 2025Global Nicotinamide Phosphoribosyl Transferase Market 2020 Industry Scenario, Strategies, Growth Factors and Forecast to 2025Global Leiomyosarcoma Drug Market 2020 Growth Parameters, Competitive Landscape Outlook and COVID-19 Impact Prediction 2025
By using this site you agree to the
As of May 30, 2020, the former fund manager holds about 2.79% shares in the company for having 2041371 shares of worth $37.74 Million while later fund manager owns 1.78 Million shares of worth $34.28 Million as of March 30, 2020, which makes it owner of about 2.44% of company’s outstanding stock.
Its founder and leader is Lewis Roberts. The company, currently valued at $1.28 Billion, closed the last trade at $17.51 per share which meant it lost -$0.34 on the day or -1.9% during that session.
Its SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm Therapeutics stock price target raised to $11 from $6 at Wedbush Jul. Over the past 30 days, the shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have changed -4.94%. The most recent analyst activity for Karyopharm Therapeutics Inc. [NASDAQ:KPTI] stock was on March 04, 2020, when it was Initiated with an Overweight rating from Barclays, which also raised its 12-month price target on the stock to $30.
Judge Esther Salas speaks about the ‘madman’ who fatally shot her son and calls for greater privacy rights Get prepared with the key expectations.There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Karyopharm Therapeutics (KPTI) and BerGenBio ...[...]FDA accepts Karyopharm supplement application for expanded use of Xpovio in multiple myelomaKaryopharm Is Trading At A Discount After Recent Additional Xpovio ApprovalKaryopharm's XPOVIO Progress And Other News: The Good, Bad And Ugly Of BiopharmaAfter RBC Capital and Canaccord Genuity gave Karyopharm Therapeutics (NASDAQ: KPTI) a Buy rating last month, the company received another Buy, this time ...[...]Karyopharm teams up with NCI to advance Xpovio researchDenovo Biopharma's enzastaurin Fast Track'd for brain tumorKaryopharm up 5% on uncertainty with advisory committee nod for Glaxo drugRhythm's Setmelanotide Data And Other News: The Good, Bad And Ugly Of BiopharmaKaryopharm Stock Down From Peak Despite Commercial Progress And Strong Data Provides Investor OpportunityKaryopharm's selinexor showed positive action in mid-stage lymphoma studyKaryopharm (KPTI) gets FDA approval for label expansion of its marketed drug, Xpovio, in relapsed or refractory diffuse large B-cell lymphoma.Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Karyopharm Therapeutics (KPTI) and Acasti Pharma ...[...]There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Karyopharm Therapeutics (KPTI) and Genocea ...[...]There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Karyopharm Therapeutics (KPTI) and Pfizer ...[...]Stocks To Watch: Nike, Apple, Ford And Stressed BanksKaryopharm Brain Cancer Trial, And Other News: The Good, Bad And Ugly Of BiopharmaKaryopharm to Report Second Quarter 2020 Financial Results on August 4, 2020Global Waldenstrom Macroglobulinemia Therapeutics Market 2020 Industry Outlook, Present Scenario of Manufacturers, Share, Size, Opportunities and Forecast to 2025U.S. Growth estimates for the current quarter are 18.3% and 4.5% for the next quarter. Revenue growth from the last financial year stood is estimated to be +158.7%.9 analysts offering their estimates for the company have set an average revenue estimate of $27.42 Million for the current quarter.
